A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
Clinical trial NCT05463419 · COMPLETED
Trial details
- NCT number
- NCT05463419
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-03
- Primary completion
- 2023-12-28
- Enrollment
- 5860
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.